文献速递心力衰竭与心肌病

左心发育不良综合征早期心力衰竭的遗传决定因素:前瞻性 NC-DEFINE 研究

Genetic Determinants of Early Heart Failure in Hypoplastic Left Heart Syndrome: A Prospective NC-DEFINE Study.
PubMed 文献 · J Am Coll Cardiol · 2026-01-01

该研究前瞻性纳入出生 21 天内的左心发育不良综合征(HLHS)新生儿,评估扩张型心肌病相关基因中超罕见变异与早期心力衰竭的关联。结果显示,携带可能致病/致病性变异的患儿发生严重心力衰竭的风险较基因阴性者高 9 倍,主要事件发生于生后第一个月内。研究提示遗传筛查可能有助于 HLHS 患儿的早期危险分层和精准管理。

要点

  • 携带扩张型心肌病相关可能致病/致病性变异的 HLHS 新生儿,严重心力衰竭风险显著升高。
  • 严重心力衰竭事件多数发生于生后第一个月内,提示早期遗传筛查具有潜在价值。
  • 不同中心队列中遗传变异与严重心力衰竭的关联方向一致,但效应大小存在差异。

核心结论

  • 本研究首次提供前瞻性证据,将扩张型心肌病相关基因变异与 HLHS 患儿的早发心力衰竭联系起来。
  • 遗传变异可能增加 HLHS 患儿的心肌易损性,遗传筛查有望用于早期危险分层和精准管理。

研究设计与样本

  • 前瞻性队列纳入杜克大学医疗系统出生 21 天内的 HLHS 新生儿 35 例。
  • 21 天以上的 HLHS 儿童和成人从杜克大学医疗系统和北卡罗来纳大学纳入双向队列。
  • 另设全国儿童医院和范德堡大学医学中心两个外部 HLHS 队列进行跨机构可重复性评估。
  • 所有参与者接受全基因组测序,评估扩张型心肌病相关基因中的超罕见变异(次要等位基因频率≤0.01%)。

主要发现

  • 35 例前瞻性队列新生儿中,7 例(20.0%)发生严重心力衰竭,10 例(28.6%)发生药物管理的心力衰竭,18 例(51.4%)无心衰。
  • 携带可能致病/致病性变异者发生严重心力衰竭的风险较基因阴性者高 9 倍(P = 0.02)。
  • 严重心力衰竭事件中 67% 发生于生后第一个月内。
  • 全国儿童医院和范德堡大学医学中心队列中,可能致病/致病性变异与严重心力衰竭的关联分别为 11 倍和 3 倍风险增加(均 P < 0.05)。
  • 双向队列中该关联减弱(均 P > 0.05),该队列年龄显著大于前瞻性队列(P < 0.0001)。

关键数值与推荐

  • 主要结局为心力衰竭,分为严重(心室辅助装置植入、心脏移植或死亡)和药物管理(体循环心室射血分数降低和/或需启动或升级抗心衰治疗的心衰诊断)。
  • 超罕见变异定义为次要等位基因频率≤0.01% 的扩张型心肌病相关基因变异。
  • 前瞻性队列中可能致病/致病性变异与严重心力衰竭的风险比值为 9(P = 0.02)。
  • 外部验证队列中对应风险比值分别为 11 和 3(均 P < 0.05)。

临床怎么用

  • 对 HLHS 新生儿可考虑将扩张型心肌病相关基因筛查纳入早期风险评估。
  • 携带可能致病/致病性变异的 HLHS 患儿需在生后第一个月内加强心力衰竭监测。

局限性

  • 前瞻性队列样本量仅 35 例,严重心力衰竭事件数有限。
  • 双向队列中遗传变异与严重心力衰竭的关联未达统计学显著性,提示年龄可能影响关联强度。
  • 未能报告具体变异位点、基因名称及其功能分类的详细信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Survivors of hypoplastic left heart syndrome (HLHS), the most severe form of congenital heart disease, are at high risk for heart failure (HF). HF in early life is a major contributor to mortality in this vulnerable population. However, reliable approaches to identify infants at highest risk for early HF are currently lacking. OBJECTIVES: The purpose of this study was to evaluate whether ultra-rare variants in cardiomyopathy-associated genes are associated with HF risk in HLHS. METHODS: Neonates with HLHS were prospectively enrolled within the first 21 days of life at Duke University Health System. Children and adults with HLHS who were older than 21 days were enrolled from Duke University Health System and the University of North Carolina into an ambispective cohort. External HLHS cohorts from Nationwide Children's Hospital and Vanderbilt University Medical Center were evaluated to assess for reproducibility across institutions. Participants underwent genome sequencing, and ultra-rare variants in dilated cardiomyopathy-associated genes (minor allele frequency ≤0.01%) were evaluated. The primary outcome was HF, categorized as severe (ventricular assist device implantation, heart transplantation, or death) or medically managed (reduced systemic ventricular ejection fraction and/or HF diagnosis requiring initiation or escalation of HF therapy). Associations between variant status and HF risk were assessed using Cox regression. RESULTS: Among 35 neonates in the prospective cohort, 7 (20.0%) developed severe HF, 10 (28.6%) developed medically managed HF, and 18 (51.4%) remained HF free. The presence of a likely pathogenic/pathogenic variant was associated with a marked 9-fold increased risk of severe HF compared with genotype-negative individuals (P = 0.02). Most severe HF events occurred within the first month of life (67%). Similar associations between likely pathogenic/pathogenic variants and severe HF were observed in the Nationwide Children's Hospital and Vanderbilt University Medical Center cohorts (11- and 3-fold increased risk, respectively; all P < 0.05). Associations were attenuated in the ambispective cohort (all P > 0.05), which consisted of individuals significantly older than the prospective cohort (P < 0.0001). CONCLUSIONS: This study provides the first prospective evidence linking dilated cardiomyopathy-associated variants to early-onset HF in HLHS. These findings suggest that genetic variation may contribute to myocardial vulnerability in HLHS, highlighting the potential for genetic screening to enable early risk stratification and guide precision medicine approaches in this high-risk population.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Balint, Sunthankar, Monaco, et al. Genetic Determinants of Early Heart Failure in Hypoplastic Left Heart Syndrome: A Prospective NC-DEFINE Study. J Am Coll Cardiol. 2026. PMID: 42714046. doi:10.1016/j.jacc.2026.06.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。